Topic: ankylosing spondylitis
Eli Lilly is busy hounding Novartis’ Cosentyx with IL-17A med Taltz. In the meantime, Taltz will settle for besting an IL-23 competitor in psoriasis.
Novartis’ Cosentyx is battling Lilly’s Taltz in three indications. Now, with new phase 3 data in spondyloarthritis, Novartis wants to make it four.
Eli Lilly’s Taltz is cruising toward blockbuster territory, and now it has a new indication to help it get there.
After underwhelming sales in the first quarter, Eli Lilly’s Taltz is on the hot seat with analysts. Long-term clear skin data could build its case.
Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all its therapy areas. But this time, Lilly wants to be first.
With some new data in hand, Eli Lilly's Taltz looks poised to challenge Novartis' Cosentyx in a third indication.
In December, Eli Lilly’s Taltz got a go-ahead to take on rival Cosentyx from Novartis in its second indication. But it’s not stopping there.